参考文献/References:
[1] Lamberts SWJ, Hofland LJ, Hofland LJ. Somatostatin anologs in the diagnosis and treatment of cancer[J]. Trends Endocrinol Metab, 2002, 13(3):451-457.
[2] 朱小华,吴华.生长抑素受体显像与放射性核素治疗[J].放射学实践,2002,17(6):546-548.
[3] Van Den, Bossche B, D’haenlnck E, De Vos F, et al. Oestrogenmediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide[J]. Eur J Med Mol Imaging, 2004, 31(7):1022-1030.
[4] Shih WJ, Samayoa L. 99mTc-depreotide detecting malignant pulmonary nodules:histopathologic correlation with semiquantitative tumor-to-normal lung ratio[J]. Clin Nucl Med, 2004, 29(3):171-176.
[5] Gsbriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-oetreotide for diagnosis of somatostatin receptor-expressing tumors[J]. J Nucl Med, 2003, 44(5):708-716.
[6] Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptorbinding peptides labeled with technetium-99m:chemistry and initial biological studies[J].J Med Chem, 1996, 39(7):1361-1371.
[7] 孙逊,安锐,李烁,等.生长抑素受体显像剂99mTc-HYNIC-TOCA和99mTc-P829在肿瘤模型中的对比研究[J].中国临床医学影像杂志,2006,17(8):438-443.
[8] Shih WJ, Hirschowitz E, Bensadoun E, et al. Biodistribution on Tc99m labeled somatostatin receptor-binding peptide (depreotide, NeoTec)planar and SPECT studies[J]. Ann Nucl Med, 2002, 16(3):213-219.
[9] Cholewinski W, Kowalczyk JR, Stefaniak B, et al. Diagnosis and staging of children’s lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide[J]. Eur J Nucl Med Mol Imaging, 2004, 31(6):820-824.
[10] Shorr AF, Helman DL, Lettieri C J, et al. Depreotide scanning in sarcoidosis:A pilot study[J]. Chest, 2004, 126(4):1337-1343.
[11] Mena E, Camacho V, Estorch M, et al.99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer[J]. Eur Nucl Med Mol Imaging, 2004, 31(10):1399-1404.
[12] Shih WJ, Romero RA, Timothy M, et al. 99mTc-Depreotide chest SPECT demonstrates pulmonary metastases from renal cell carcinoma[J]. J Nucl Med Technol, 2004, 32(1):19-21.
[13] Van Den Bossche B, D’haeninck E, Bacher K, et al. Biodistribution and dosimetry of 99mTc-depreotide(P829)in patients suffering from breast carcinoma[J]. Cancer Biother Radiopharm, 2004, 19(6):776-783.
[14] 王峰,王自正,姚薇萱,等.99mTc-生长抑素受体显像对肺癌的诊断价值[J].中华结核和呼吸杂志,2005,28(4):218-220.
[15] Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours[J]. Best Pratt Res Clin Endocrinol Metab, 2005, 19(2):265-276.
[16] Blum JE, Handmaker H, Rinne NA. The utility of a somatostatintype receptor binding peptide radiopharmaceutical (P829)in the evaluation of solitary pulmonary nodules[J]. Chest, 1999, 115(1):224-232.
[17] Blum J, Handmaker H, Lister-James J, et al. A multieenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules[J]. Chest, 2000, 117(5):1232-1238.
[18] Kahn D, Menda Y, Kemstine K, et al.The utility of 99mTc-depreotide compared with 18F-fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected nonsmall cell lung cromer[J]. Chest, 2004, 125(2):497-501.
[19] 王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217-219.
[20] Valsamaki P, Gotzamani-Psarrakou A, Tsiouris S, et al. 99mTc-depreotide imaging of 131I-negative recurrent metastatic papillary thyroid carcinoma[J].Int J Cancer, 2006, 119(4):968-970.
[21] Hellwig D, Samnik M, Reif J, et al. Comparison of 99mTc-depreotide and Indium-111 octreotide in recurrent meningioma[J]. Clin Nucl Med, 2002, 27(11):781-784.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[13]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[14]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):217.
[15]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):154.
[16]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):17.
[17]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(1):220.